Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats

Urological Research

Volumn 39, Issue 3, 2011, Pages 189-195

  Vanachayangkul, P ^a   Chow, N ^a   Khan, S R ^b   Butterweck, Veronika ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Ammi visnaga; Apiaceae; Calcium oxalate; Hyperoxaluria; Khellin; Nephrolithiasis; Visnagin

Indexed keywords

AMMONIUM CHLORIDE; AMNI VISNAGA EXTRACT; ETHYLENE GLYCOL; KHELLIN; PLANT EXTRACT; UNCLASSIFIED DRUG; VISNAGIN;

AMNI VISNAGA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INHIBITION; HISTOPATHOLOGY; HYPEROXALURIA; INCIDENCE; MALE; MEDICINAL PLANT; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; URINE PH;

ADMINISTRATION, ORAL; AMMI; ANIMALS; CALCIUM OXALATE; DISEASE MODELS, ANIMAL; HYPEROXALURIA; KHELLIN; KIDNEY; KIDNEY CALCULI; MALE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 80051663519     PISSN: 03005623     EISSN: 14340879     Source Type: Journal    
DOI: 10.1007/s00240-010-0333-y     Document Type: Article

References (31)

1. Atmani F, Slimani Y, Mimouni M, Hacht B (2003) Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats. BJU Int 92:137-140 (Pubitemid 36843044)
2. Butterweck V, Khan SR (2009) Herbal medicines in the man-agement of urolithiasis: alternative or complementary? Planta Med 75:1095-1103
3. Chow K, Dixon J, Gilpin S, Kavanagh JP, Rao PN (2004) Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int 65:1724-1730 (Pubitemid 38591020)
4. Colussi G, De Ferrari ME, Brunati C, Civati G (2000) Medical prevention and treatment of urinary stones. J Nephrol 13:S65-S70
5. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273-3277 (Pubitemid 19143549)
6. Gerstenbluth RE, Resnick MI (2004) Medical management of calcium oxalate urolithiasis. Med Clin North Am 88:431-442 (Pubitemid 38231017)
7. Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG (1989) Urine citrate and renal stone disease. Can Med Assoc J 141:217-221 (Pubitemid 19195785)
8. Gunaydin K, Beyazit N (2004) The chemical investigations on the ripe fruits of Ammi visnaga (LAM.) Lamarck growing in Turkey. Nat Prod Res 18:169-175 (Pubitemid 38213216)
9. Huang HS, Ma MC, Chen J, Chen CF (2002) Changes in the oxidant-antioxidant balance in the kidney of rats with nephroli-thiasis induced by ethylene glycol. J Urol 167:2584-2593 (Pubitemid 34533185)
10. Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15:236-243 (Pubitemid 127764011)
11. Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349-357 (Pubitemid 41752056)
12. Khan SR (2006) Renal tubular damage/dysfunction: key to the formation ofkidney stones. Urol Res 34:86-91
13. Khan SR, Glenton PA, Byer K (2006) Modeling ofhyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int 70:914-923 (Pubitemid 44285969)
14. Khan ZA, Assiri AM, Al-Afghani HM, Maghrabi TM (2001) Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI-Khillah). Int Urol Nephrol 33:605-608 (Pubitemid 35282640)
15. Knoll T (2007) Stone disease. Euro Urol Suppl 6:717-722 (Pubitemid 46720122)
16. Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215: 383-389 (Pubitemid 14111516)
17. Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate\-a critical review. Urol Res 33:73-79 (Pubitemid 40921945)
18. Modlinger PS, Welch WJ (2003) Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12:497-502 (Pubitemid 37083109)
19. Pak CY (1987) Citrate and renal calculi. Miner Electrolyte Metab 13:257-266 (Pubitemid 17149578)
20. Pak CY (1991) Etiology and treatment of urolithiasis. Am J Kidney Dis 18:624-637
21. Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323-334 (Pubitemid 47189601)
22. Poulsen SA, Quinn RJ (1998) Adenosine receptors: new oppor-tunities for future drugs. Bioorg Med Chem 6:619-641 (Pubitemid 28287266)
23. HW Boao, KP Rauwald (1994) The involvement of a Ca2+ channel blocking mode of action in the pharmacology of Ammi visnaga fruits. Planta Med 60:101-105
24. Renata C, Fabio V, Angela B, Sergio S (2003) Citrate and min-eral metabolism: kidney stones and bone disease. Front Biosci 8:S1084-S1106 (Pubitemid 38925372)
25. Sakhaee K, Alpern R, Poindexter J, Pak CYC (1992) Citraturic response to oral citric-acid load. J Urol 147:975-976
26. Sarica K, Inal Y, Erturhan S, Yagci F (2006) The effect of cal-cium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34:184-189
27. Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758-767
28. Unwin RJ, Capasso G, Shirley DG (2004) An overview of divalent cation and citrate handling by the kidney. Nephron Physiol 98:15-20
29. Vanachayangkul P, Byer K, Khan S, Butterweck V (2010) An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 17:653-658
30. Worcester EM, Coe FL (2008) Nephrolithiasis. Prim Care 35:369-391 (vii) (Pubitemid 351680115)
31. Yuliana ND, Khatib A, Link-Struensee AM, Ijzerman AP, Rungkat-Zakaria F, Choi YH, Verpoorte R (2009) Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosi-phon stamineus. Planta Med 75:132-136